Buy, Sell or Hold: Abiomed (ABMD-Q)

Home

Daily Stock Opinions and Ratings

Abiomed (ABMD-Q)

NASDAQ:ABMD

381.50

0.48 (0.13%) 1d

Nervous markets await Nvidia

BUY

Medical device-makers are safe in a weakening economy. Shares have soared over the past 12 years by 1,350%. The pandemic caused a big delay in surgeries, but it's now time for ABMD to shine. Their products (treating heart disease) are in high demand. Their most recent quarter was really good. True, this stock isn't cheap, but not neither are their peers.

Showing 1 to 1 of 1 entries

Abiomed(ABMD-Q) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Abiomed is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Abiomed(ABMD-Q) Frequently Asked Questions

What is Abiomed stock symbol?

Abiomed is a American stock, trading under the symbol ABMD-Q on the NASDAQ (ABMD). It is usually referred to as NASDAQ:ABMD or ABMD-Q

Is Abiomed a buy or a sell?

In the last year, there was no coverage of Abiomed published on Stockchase.

Is Abiomed a good investment or a top pick?

Abiomed was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Abiomed.

Why is Abiomed stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Abiomed worth watching?

0 stock analysts on Stockchase covered Abiomed In the last year. It is a trending stock that is worth watching.

What is Abiomed stock price?

On 2022-12-21, Abiomed (ABMD-Q) stock closed at a price of $381.5.

Most Recent Experts

Stockchase Insights

5i Research

Michael Hakes - CFA, MBA

Murray Wealth Group

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Cerity Partners

Brenda Vingiello, CIO, Sand Hill Global Advisors

Sand Hill Global Advisors

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.